A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis
Authors' conclusion
Romosozumab provides real-world efficacy in BMD improvement, particularly at the LS, with significantly greater gains than those seen with teriparatide or standard therapies.
Study context
- Population
- Patients with osteoporosis treated at tertiary hospitals in Australia, 2021–23
- Participants
- 53 / 54 / 60
- Exposure
- Romosozumab vs teriparatide vs antiresorptive therapy
- Romosozumabn = 53
- Teriparatiden = 54
- Anti-resorptiven = 60reference
- Outcome
- Change in BMD (LS, TH, FN, wrist)
- Follow-up
- 12 months
Methodological detailstwo-centre, real-world
- Two-centre
- Real-world
Main finding
As reported in the abstract
Mean LS BMD gain
Romosozumab vs Teriparatide: P < 0.001 · Romosozumab vs Anti-resorptive: P < 0.001
- Romosozumab increased bone mineral density (BMD) at lumbar spine (LS), total hip (TH) and femoral neck (FN), with a decrease at the wrist
- P < 0.05
Observational data: associations, not effects.
Further findings
LS BMD gain on romosozumab, treatment-naïve vs prior anti-resorptive (subgroup)
P = 0.220
TH BMD gain on romosozumab, treatment-naïve vs prior anti-resorptive (subgroup)
P = 0.009
Correlation of prior anti-resorptive duration with LS BMD gain on romosozumab
- R
- - 0.305
- P
- P = 0.026
Linear regression of LS BMD response
- More vertebral fractures, longer prior anti-resorptive use and higher baseline LS BMD each attenuated LS BMD response to romosozumab; romosozumab outperformed teriparatide and anti-resorptives; teriparatide showed no significant difference from anti-resorptives
Original publication
A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis. Osteoporos Int. Published 20 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →